Heron Therapeutics, Inc. (0J4V.L)
USD 1.62
(0.31%)
USD 1.62
(0.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -110.55 Million USD | 39.26% |
| 2022 | -182.02 Million USD | 17.52% |
| 2021 | -220.68 Million USD | 2.9% |
| 2020 | -227.27 Million USD | -11.0% |
| 2019 | -204.74 Million USD | -14.49% |
| 2018 | -178.84 Million USD | 9.44% |
| 2017 | -197.48 Million USD | -14.06% |
| 2016 | -173.14 Million USD | -77.42% |
| 2015 | -97.59 Million USD | -27.79% |
| 2014 | -76.36 Million USD | -38.14% |
| 2013 | -55.28 Million USD | -126.29% |
| 2012 | -24.43 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.16 Million USD | 70.53% |
| 2024 Q2 | -9.23 Million USD | -192.25% |
| 2023 Q1 | -32.76 Million USD | -64.92% |
| 2023 Q3 | -25 Million USD | 40.54% |
| 2023 Q4 | -10.72 Million USD | 57.12% |
| 2023 FY | -110.55 Million USD | 39.26% |
| 2023 Q2 | -42.05 Million USD | -28.35% |
| 2022 FY | -182.02 Million USD | 17.52% |
| 2022 Q3 | -41.9 Million USD | 25.64% |
| 2022 Q2 | -56.35 Million USD | 11.78% |
| 2022 Q1 | -63.88 Million USD | -16.91% |
| 2022 Q4 | -19.86 Million USD | 52.59% |
| 2021 Q4 | -54.64 Million USD | -4.27% |
| 2021 Q2 | -61.01 Million USD | -15.97% |
| 2021 Q3 | -52.4 Million USD | 14.11% |
| 2021 FY | -220.68 Million USD | 2.9% |
| 2021 Q1 | -52.61 Million USD | 15.52% |
| 2020 Q3 | -58.22 Million USD | -5.5% |
| 2020 Q4 | -62.28 Million USD | -6.96% |
| 2020 FY | -227.27 Million USD | -11.0% |
| 2020 Q1 | -51.57 Million USD | 10.95% |
| 2020 Q2 | -55.19 Million USD | -7.0% |
| 2019 Q1 | -63.01 Million USD | -27.15% |
| 2019 Q2 | -50.22 Million USD | 20.3% |
| 2019 Q4 | -57.92 Million USD | -72.41% |
| 2019 FY | -204.74 Million USD | -14.49% |
| 2019 Q3 | -33.59 Million USD | 33.11% |
| 2018 FY | -178.84 Million USD | 9.44% |
| 2018 Q4 | -49.55 Million USD | -29.24% |
| 2018 Q3 | -38.34 Million USD | 0.84% |
| 2018 Q2 | -38.67 Million USD | 26.01% |
| 2018 Q1 | -52.26 Million USD | 16.36% |
| 2017 FY | -197.48 Million USD | -14.06% |
| 2017 Q2 | -42.79 Million USD | 14.96% |
| 2017 Q3 | -41.86 Million USD | 2.18% |
| 2017 Q4 | -62.49 Million USD | -49.26% |
| 2017 Q1 | -50.32 Million USD | -4.93% |
| 2016 Q3 | -48.5 Million USD | -12.22% |
| 2016 FY | -173.14 Million USD | -77.42% |
| 2016 Q2 | -43.22 Million USD | -29.25% |
| 2016 Q1 | -33.44 Million USD | -7.05% |
| 2016 Q4 | -47.96 Million USD | 1.13% |
| 2015 FY | -97.59 Million USD | -27.79% |
| 2015 Q4 | -31.24 Million USD | -37.8% |
| 2015 Q1 | -20.57 Million USD | 0.26% |
| 2015 Q3 | -22.67 Million USD | 1.88% |
| 2015 Q2 | -23.1 Million USD | -12.33% |
| 2014 Q2 | -19.01 Million USD | -8.4% |
| 2014 Q3 | -19.19 Million USD | -0.96% |
| 2014 FY | -76.36 Million USD | -38.14% |
| 2014 Q1 | -17.53 Million USD | -24.89% |
| 2014 Q4 | -20.62 Million USD | -7.45% |
| 2013 FY | -55.28 Million USD | -126.29% |
| 2013 Q4 | -14.04 Million USD | -9.09% |
| 2013 Q1 | -12.95 Million USD | -46.78% |
| 2013 Q3 | -12.87 Million USD | 16.48% |
| 2013 Q2 | -15.41 Million USD | -18.99% |
| 2012 Q4 | -8.82 Million USD | 0.0% |
| 2012 FY | -24.43 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 27.842% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1630.459% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 8501.14% |
| Perrigo Company plc | -12.7 Million USD | -770.543% |
| Illumina, Inc. | -1.16 Billion USD | 90.477% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.844% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 75.101% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.72% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 108.141% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.796% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -177.368% |
| Waters Corporation | 642.23 Million USD | 117.215% |
| Biogen Inc. | 1.16 Billion USD | 109.522% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 57.12% |
| Evolus, Inc. | -61.68 Million USD | -79.232% |
| Adicet Bio, Inc. | -142.65 Million USD | 22.501% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 6.712% |
| bluebird bio, Inc. | -211.91 Million USD | 47.828% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 47.164% |
| FibroGen, Inc. | -284.23 Million USD | 61.103% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 108.916% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -147.872% |
| Homology Medicines, Inc. | -53.74 Million USD | -105.718% |
| Geron Corporation | -184.12 Million USD | 39.955% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 74.887% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 27.064% |
| Myriad Genetics, Inc. | -112 Million USD | 1.287% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -28.714% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 77.024% |
| Zoetis Inc. | 2.34 Billion USD | 104.717% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -104.029% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 114.016% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 165.948% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.054% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -161.994% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 69.816% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 59.961% |
| Verastem, Inc. | -87.36 Million USD | -26.545% |
| Nektar Therapeutics | -276.05 Million USD | 59.951% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 53.787% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -24.952% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 79.372% |
| OPKO Health, Inc. | -188.86 Million USD | 41.461% |
| Exelixis, Inc. | 207.76 Million USD | 153.213% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 144.277% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 204.163% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -132.731% |
| uniQure N.V. | -308.47 Million USD | 64.16% |
| Imunon, Inc. | -19.51 Million USD | -466.534% |
| Blueprint Medicines Corporation | -506.98 Million USD | 78.193% |
| Insmed Incorporated | -749.56 Million USD | 85.25% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 139.262% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 68.599% |
| TG Therapeutics, Inc. | 12.67 Million USD | 972.467% |
| Incyte Corporation | 597.59 Million USD | 118.501% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 85.462% |